# Introduction ARS (severe acute respiratory syndrome) is the severe stage of COVID-19 caused by massive alveolar damage and progressive respiratory failure; caused by SARS-CoV-2 (SARS coronavirus 2) 1 . SARS-CoV-2 belongs to the family Coronaviridae, subfamily Orthocoronaviridae. It is a single-stranded RNA virus, whose genome is around 27-32 kb, which encodes non-structural proteins, such as proteases, helicases, and RNA polymerases: and structural proteins 2,3 COVID-19 can be divided into three phases: asymptomatic with or without detectable virus; nonsevere symptomatic with the presence of virus and severe respiratory symptomatic with high viral load 4 . An unresolved question is why some develop serious illness and others do not. Aspects based on the immune response are not enough to explain it, but they will help to understand the behavior of this new pathogen 5 . Author: Engineer. Master's in educational technology management, Specialist in Educational Informatics Administration. Mathematics teacher and researcher, institutional affiliation: Secretary of Education of Soacha, Colombia. e-mail: jediazp@unal.edu.co The rapid obligation of vaccines against COVID-19 has forced the use of proteomics to search for exclusive antigens of the pathogen in protein S. Thanks to bioinformatics, 933 pentapeptides absent in the human proteome have been recognized, of which 107 peptides are located around protein S and of these 66 peptides are more immunogenic and can be used in the production of a vaccine 6 . The WHO has up to 52 alternative vaccine candidates between platforms based on proteins, RNA, DNA, non-vectors. replicants, replicating vectors, inactivated viruses, attenuated viruses, and virus-like particles. Of all these vaccine inserts, only vaccines made up of RNA and nonreplicating vector have initiated safety studies in humans 7,8. To achieve a continued reduction in infection cases 9 multiple countermeasures are needed, including distancing, testing, and tracing, especially considering the recent emergence of new variants of SARS-CoV-2 10 , such as B.1.1.7 and B.1.351, which are reported to have higher transmissibility 11,12 and are likely to cause more severe disease 13 compared to the parent strain. Vaccination alone is not expected to counteract the spread of infection, and a carefully planned vaccination campaign needs to be regulated 14,15 The objective of this research is to show the behavior of the incidence of COVID-19 and vaccination against SARS-COV-2, between the period between February 17 to September 30, 2021. # II. # Methodology This research was carried out under a crosssectional study [16][17][18] , the information was obtained from the website of the Ministry of Health and Social Protection 19 of the daily reports of contagion by COVID-19, between the period between January 1, 2021, and September 30, 2021, to calculate the incidence, and from February 17 to September 30, 2021, for vaccination. # III. # Results Table 1 shows the months between January and September 2021, the new cases of infection by SARS-CoV-2, the vaccines, and the population in Colombia. With the information in columns 2 and 3, the incidence rate was calculated in percentage terms for COVID-19. Source: the autor Figure 1 shows the incidence by months for SARS-CoV-2, between the months of January to September 2021 and the vaccination against COVID-19, between the months of February to September 2021. It describes a similarity in the trend of the incidence lines (blue), and vaccination (orange), that is, while the incidence increases over time, the number of vaccines also increases, this trend is maintained until June. From the month of July to September there is a decrease in the incidence of SARS-CoV-2, as well as the decrease in the application of the number of vaccines. IV. # Source: the author # Conclusions From the data analyzed, it is concluded that the incidence of COVID-19 is related to vaccination until June 2021 against SARS-COV-2, that is, as vaccination values increase, Incidence cases due to COVID-19 also increase and a contrary situation from July to September, that is, as vaccination values decrease, incidence cases due to COVID-19 also decrease. There is a demand for more studies predestined to evaluate the efficacy of vaccination in reducing the transmission of SARS-CoV-2 in Colombia, both at the individual level and at the population level, with greater longitudinal screening and in additional populations 20 . Monitoring the results of vaccinations is essential to understand efficacy, possible decline in immune response over time, and possible adverse effects. Monitoring the effects of these vaccines is possible and much needed. The publication of these data, duly verified, is a priority. For this, it would be very important to follow the vaccinated and check if they suffer from COVID-19 infections, and sequence where appropriate. 1MonthsNew casesPopulationIncidenceVaccinesJanuary451609510494980,88February156856505978890,31130578March154687504410330,312112814April453347502863460,92743079May543805498329991,095105651June834526492891941,698189621July533290484546681,19242634August123766479213780,268021788September48191477976120,105159042 © 2021 Global JournalsBehavior of the Incidence of COVID-19 and Vaccination against SARS-Cov-2 in Colombia * Pathological findings of COVID-19 associated with acute respiratory distress syndrome ZXu LShi Wang JZhang LHuang CZhang 10.1016/S2213-2600(20)30076-X Lancet Respir Med 2600 20 2020 * Singlecell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection XZou KChen JZou PHan JHao ZHan Doi: 10.1007/ s11684-020-0754-0 Front Med [Internet]. 2020; 1-8 * Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 BShanmugaraj KSiriwattananon KWangkanont WPhoolcharoen COVID-19 * 10.12932/AP-200220-0773 Asian Pac J Allergy Immunol 2020 * COVID-19 infection: the perspectives on immune responses YShi YWang CShao JHuang JGan XHuang 10.1038/s41418-020-0530- Cell Death Differ 2020 * COVID-19: respuestainmune y perspectivas terapéuticas ILozada-Requena CNúñez-Ponce 10.17843/rpmesp.2020.372.5490 Revista Peruana de Medicina Experimental y 37 2 Apr-Jun 2020 * Epitopes for a 2019-nCoV vaccine GLucchese Doi: 10.1038/ s41423-020-0377-z Cell Mol Immunol [Internet] 2020 * Vaccine designers take first shots at COVID-19 JCohen 10.1126/science.368.6486.14 Science [Internet] 368 6486 2020 * Developing Covid-19 Vaccines at Pandemic Speed NLurie MSaville RHatchett JHalton 10.1056/NEJMp N Engl J Med [Internet] 2020. 2005630 * Pidiendo un compromiso paneuropeo para una reducción rápida y sostenida de las infecciones por SARS-CoV-2 VPriesemann Lancet 397 2021 * Un plan de acción para la defensa paneuropea contra las nuevas variantes del SARS-CoV-2 VPriesemann Lancet 397 2021 * Transmisibilidad e impacto estimados del linaje B.1.1.7 del SARS-CoV-2 en Inglaterra Davies Science 372 3055 2021 * & CMMID COVID-19 Working Group. Números de reproducción del área local y falla del objetivo del gen S SAbbott SFunk 2021 * Nota de NERVTAG sobre la gravedad de B.1.1.7 PHorby 2021 * Estrategias de priorización de la vacuna COVID-19 basad as en modelos por edad y estado serológico Bubar Science 371 2021 * Modelización del impacto de las variantes y vacunas del SARS-CoV-2 en la propagación del COVID-Preprint in ResearchGate AMRamos MVela-Pérez Ferrández Mr Kubik BIvorra 10.13140/RG.2.2.32580.24967/2(2021 * Estimación de la prevalencia del COVID-19 en Colombia JEDíaz Pinzón 10.31260/RepertMedCir.01217372.1115 Revista Repertorio De Medicina Y Cirugía 2020 * Descripción estadística del COVID-19 según el grupo etario en Colombia JEDíaz Pinzón 10.31260/RepertMedCir.01217372.1098 Revista Repertorio De Medicina Y Cirugía 2020 * Estimación de la prevalencia del COVID-19 en Colombia JEDíaz Pinzón 10.31260/RepertMedCir.01217372.1115 Revista Repertorio De Medicina Y Cirugía 2020 * Ministerio de Salud y protección Social. Vacunación contra COVID-19 citado 05 de octubre de 2021 * Dinámica y relación del contagio del COVID-19 después de iniciado el plan de vacunación contra JEDíaz Pinzón el SARS-COV-2 en 2021 * Colombia YRevista Repertorio De Medicina Cirugía 10.31260/RepertMedCir.01217372.1227